Apogee Therapeutics Plans To Highlight Updates From Across Its Pipeline During Virtual R&D Day
Apogee Therapeutics Plans To Highlight Updates From Across Its Pipeline During Virtual R&D Day
Apogee Therapeutics计划在虚拟研发日活动中突出其各个项目的更新
Updates include interim results from the APG808 Phase 1 trial, data up to 12 months from the APG777 Phase 1 trial, details around the Company's strategy for combinations in AD, asthma and COPD to deliver better efficacy and dosing regimens, and the expected significant commercial potential of its programs.
更新包括APG808相位1试验的中期结果，APG777相位1试验长达12个月的数据，公司在AD、哮喘和COPD组合策略方面的详细信息，以提供更好的疗效和给药方案，以及其项目预期的显著商业潜力。
Data up to 12 months reinforce APG777's best-in-class potential, including 77-day half-life, and provide a potential path to annual dosing.
长达12个月的数据强化了APG777的最佳潜力，包括77天的半衰期，并提供了年度用药的潜在途径。
资讯热榜
更新时间